证券日报网讯12月19日，健民集团（600976）在互动平台回答投资者提问时表示，公司始终聚焦主业发 展，提高持续经营能力、核心竞争力和投资价值，积极回报公司股东，并通过投资者关系管理活动保持 与市场的良性沟通。目前公司经营情况正常。 ...

健民药业集团股份有限公司 关于氨溴特罗口服溶液获批上市的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 近日，健民药业集团股份有限公司（以下简称"公司"）从国家药品监督管理局网站获悉，公司研发的氨 溴特罗口服溶液获批上市。现将相关情况公告如下： 一、药品获批上市的主要内容 药物名称：氨溴特罗口服溶液 证券代码：600976 证券简称：健民集团 公告编号：2025-038 二、药品研发及相关情况 剂型：口服溶液剂 规格：100ml：盐酸氨溴索150mg与盐酸克仑特罗100μg 申请事项：药品注册（境内生产） 注册分类：化学药品3类 药品受理号：CYHS2201805 药品批准文号：国药准字H20256088 药品批准文号有效期：至2030年12月02日 上市许可持有人：健民药业集团股份有限公司 生产企业：健民药业集团股份有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注册的有关要求， 批准注册，发给药品注册证书。质量标准、说明书、标签及生产工艺照所附执行。药品生产企业应当符 合药品 ...

Group 1 - Jicheng Electronics won a total of 15 bids from the State Grid Corporation, with a total bid amount of approximately 215 million yuan, accounting for 8.27% of the company's projected revenue for 2024 [2] - Jianmin Group's chemical generic drug, Ambrutoro Oral Solution, has been approved for market launch by the National Medical Products Administration, aimed at treating cough and wheezing caused by chronic bronchitis and emphysema [3] - Taiji Industry's subsidiary plans to transfer accounts receivable not exceeding 85 million USD to optimize cash flow, with an expected service fee of approximately 285,000 USD [4] Group 2 - Nanjing Pharmaceutical's subsidiary plans to invest 398 million yuan in a modern pharmaceutical logistics expansion project, with a construction period of approximately 35 months [5] - Ruili Kemi received a development notification from a well-known domestic flying car company to supply core components [6] - Ding Tong Technology announced that several executives plan to reduce their holdings by a total of no more than 45,300 shares, representing about 0.032% of the total share capital [7][8] Group 3 - Ninghu Expressway's subsidiary plans to invest no more than 9.033 billion yuan in the construction of the Nanyang Yangtze River Bridge South Connection Project [10] - Wuliangye announced a mid-term profit distribution plan for 2025, proposing a cash dividend of 25.78 yuan per 10 shares, totaling approximately 10 billion yuan [12] - Beixin Road and Bridge's subsidiary won a bid for a project worth 180 million yuan [14] Group 4 - Minhe Livestock reported a 7.75% month-on-month increase in sales revenue from commodity chick sales in November [15] - Xuelong Group plans to invest 100 million yuan to establish a wholly-owned subsidiary for vertical integration in the aluminum and magnesium technology sector [16] - Shengnong Development reported a 15.77% year-on-year increase in sales revenue in November, with significant growth in both poultry and processed meat products [17] Group 5 - Xingyu Co., Ltd. plans to repurchase shares worth 200 million to 300 million yuan for employee stock ownership plans [18] - Quan Chai Power intends to use 50 million yuan of idle funds to purchase structured deposit products [19] - Shibei High-tech appointed Zhao Junhong as the new deputy general manager [20] Group 6 - Fuan Pharmaceutical's subsidiary received a drug registration certificate for injectable isavuconazole, expanding its anti-infection product line [21] - Xiaoming Co. reported a 49.73% year-on-year decline in chicken product sales revenue in November [22] - Baiao Chemical adjusted its share repurchase price ceiling to no more than 48.95 yuan per share [23] Group 7 - Hefei China reported a 26.02% year-on-year decline in consolidated revenue for the first 11 months [24] - Laimei Pharmaceutical's subsidiary received medical device registration certificates for two endoscope products [25][26] - Xiantan Co. reported an 11.63% year-on-year increase in chicken product sales revenue in November [27] Group 8 - Qilin Security received government subsidies totaling 5.4014 million yuan [28] - Blue Sky Gas's controlling shareholder's 30.9134 million shares were judicially frozen, accounting for 4.33% of the total share capital [29] - Tieke Railway signed a contract for high-speed railway fasteners worth 654 million yuan, accounting for 41.08% of the company's projected revenue for 2024 [30] Group 9 - David Medical's electric surgical table received a medical device registration certificate [31] - Zhendong Pharmaceutical's affiliate's core product new drug application was accepted by the CDE [32] - Shanghai Pharmaceutical's apple acid sitagliptin tablet application for market approval was granted by the National Medical Products Administration [33] Group 10 - Nanjiao Food reported a 1.14% year-on-year increase in consolidated revenue for November [34]

健民药业集团股份有限公司 关于氨溴特罗口服溶液获批上市的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，健民药业集团股份有限公司（以下简称"公司"）从国家药品监督管 理局网站获悉，公司研发的氨溴特罗口服溶液获批上市。现将相关情况公告如下： 一、药品获批上市的主要内容 证券代码：600976 证券简称：健民集团 公告编号：2025-038 上市许可持有人：健民药业集团股份有限公司 生产企业：健民药业集团股份有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求 方可生产销售。 药物名称：氨溴特罗口服溶液 剂型：口服溶液剂 规格：100ml：盐酸氨溴索 150mg 与盐酸克仑特罗 100μg 申请事项：药品注册（境内生产） 注册分类：化学药品 3 类 药品受理号：CYHS2201805 药品批准文号：国药准字 H20256088 药品批准文号有效期： ...

氨溴特罗口服溶液是由盐酸氨溴索和盐酸克仑特罗组成的复方制剂。其中盐酸氨溴索为粘液溶解剂，能 降低痰液粘度，使痰液易于咳出；盐酸克仑特罗为选择性β受体激动剂，有松弛支气管平滑肌、促进痰 液排出的作用。两种成分起到很好的止咳排痰协同作用。公司研发的该品种与原研参比制剂有相同的活 性成分、辅料、剂型、规格、适应症、给药途径和用法用量，该品种临床应用成熟，市场容量较大。 格隆汇12月10日丨健民集团(600976.SH)公布，近日，公司从国家药品监督管理局网站获悉，公司研发 的氨溴特罗口服溶液获批上市。药物名称：氨溴特罗口服溶液，药品受理号：CYHS2201805，药品批 准文号：国药准字 H20256088。 公司研发的化学药仿制药氨溴特罗口服溶液获批上市，将进一步丰富公司产品线，有利于提升公司核心 竞争力，对公司未来发展产生积极影响。 ...

Investment Rating - The industry rating is maintained at "Overweight" [8] Core Views - The market performance of the traditional Chinese medicine (TCM) sector showed a slight increase of 1.29%, which is the smallest among secondary sub-sectors [1] - The price governance of Chinese patent medicines is being actively implemented across multiple regions, aiming to create a unified and competitive drug market [4][5] - The valuation metrics for the TCM sector indicate a PE (ttm) of 27.72X and a PB (lf) of 2.33X, with both metrics showing slight increases compared to the previous week [2] Market Performance - The TCM sector reported a market index of 6501.99 points, reflecting a 1.29% increase over the last week [1] - The overall pharmaceutical and biological sector index rose to 8430.03 points, with a 2.67% increase [1] Valuation Metrics - The TCM sector's PE (ttm) is at 27.72X, up by 0.36X week-on-week, with a one-year maximum of 30.26X and a minimum of 24.72X [2] - The PB (lf) stands at 2.33X, increasing by 0.02X from the previous week, with a one-year maximum of 2.54X and a minimum of 2.17X [2] Supply Chain Insights - The market for TCM raw materials has shown signs of recovery, with a price index of 225.55 points, reflecting a 0.4% increase from the previous week [3] - The market sentiment for TCM raw materials is improving, with increased foot traffic and positive investment sentiment [3] Policy and Regulatory Environment - Multiple regions have initiated price governance for Chinese patent medicines, focusing on high-priced products with significant price discrepancies [4][5] - The ongoing supply-side reforms are expected to reshape competitive factors within the industry, with a shift from channel-driven to value and cost-driven competition [5] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [11] - Specific recommendations include companies with strong R&D capabilities, unique products, and those less affected by centralized procurement [12]

Core Viewpoint - The company has announced a guarantee for its subsidiary, Wuhan Jianmin Pharmaceutical Group Weisheng Pharmaceutical Co., Ltd., to secure a bank credit line of 25 million yuan from Bank of Communications Hanyang Branch for operational needs [2][6]. Summary by Sections Guarantee Overview - The guaranteed amount is 25 million yuan with a one-year term, aimed at supporting the subsidiary's daily operational cash flow [2][6]. - The company will provide a joint liability guarantee for the credit line application, which includes various financial products such as working capital loans and bank acceptance bills [2][4]. Internal Decision-Making Process - The company's board approved the guarantee during the 33rd meeting of the 10th board on March 20, 2025, and it was subsequently ratified at the annual shareholders' meeting on April 15, 2025 [3][7]. - The company has a total guarantee limit of up to 100 million yuan for its subsidiaries, with no existing guarantees for Weisheng prior to this announcement [3][8]. Subsidiary Information - Weisheng is a wholly-owned subsidiary of the company, currently in good operational and credit standing, indicating a manageable risk for the guarantee [6][8]. Guarantee Agreement Details - The guarantee covers all principal and interest obligations under the main contract, including various financing costs [4][5]. - The guarantee period is calculated based on the repayment terms of the main debts, extending up to three years after the last due date [5]. Necessity and Reasonableness of the Guarantee - The guarantee is deemed necessary to support the subsidiary's operational funding needs, which will enhance its financing capabilities and alleviate liquidity pressure [6][8]. - The company has a history of providing guarantees for its subsidiaries without any overdue obligations [6][8]. Cumulative Guarantee Situation - As of the announcement date, the total guarantee amount provided by the company to its subsidiaries is 356 million yuan, representing 14.62% of the company's audited net assets of approximately 2.435 billion yuan [8]. - There are no overdue guarantees or obligations requiring the company to assume responsibility [8].

Core Viewpoint - Jianmin Group (600976) announced that the company does not have any overdue guarantees or guarantees that require the company to assume responsibility upon expiration [1] Summary by Category - **Company Announcement** - Jianmin Group confirmed the absence of overdue guarantees [1] - The company stated there are no guarantees that will require it to take on responsibility upon expiration [1]

Group 1 - The core point of the article is that Jianmin Group has provided a total guarantee of 356 million yuan to its controlling subsidiaries, which represents 14.62% of the company's audited net assets of approximately 2.435 billion yuan for 2024 [1] - As of October 30, 2025, the remaining guarantee balance provided by the company to its controlling subsidiaries is approximately 121 million yuan [1] - The revenue composition of Jianmin Group for the year 2024 is as follows: pharmaceutical manufacturing accounts for 49.83%, pharmaceutical commerce accounts for 49.56%, and other businesses account for 0.6% [1] - The current market capitalization of Jianmin Group is 5.8 billion yuan [1]

证券代码：600976 证券简称：健民集团 公告编号：2025-037 健民药业集团股份有限公司 关于为子公司银行授信额度提供担保实施的公告 被担保人：武汉健民药业集团维生药品有限责任公司 债权人：交通银行股份有限公司汉阳支行 担保金额：2,500 万元 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 担保 对象 被担保人名称 武汉健民药业集团维生药品有限责任公司 （以下简称"维生公司"） 本次担保金额（万元） 2,500 实际为其提供的担保余额 0 是否在前期预计额度内 是 □否 □不适用：_________ 本次担保是否有反担保 □是 否 □不适用：_________ 累计担保情况 | 对外担保逾期的累计金额（万元） 0 | | | --- | --- | | 截至本公告日上市公司及其控股子 公司对外担保总额（万元） | 12,071 | | 对外担保总额占上市公司最近一期 经审计净资产的比例（%） | 14.62 | | 特别风险提示（如有请勾选） | □对外担保总额（含本次）超过上市 ...